Price (delayed)

$59.14

Market cap

$133.82B

P/E Ratio

92.41

Dividend/share

$1.76

EPS

$0.64

Enterprise value

$164.7B

Sector: Healthcare

Industry: Drug Manufacturers - General

Website: http://www.bms.com

The company's revenue rose by 33% YoY and by 19% QoQ

Bristol Myers Squibb Co's gross profit has increased by 27% YoY and by 17% from the previous quarter

The quick ratio has decreased by 16% YoY but it has increased by 10% QoQ

The stock's price to earnings (P/E) is 154% more than its last 4 quarters average of 36.4 and 71% more than its 5-year quarterly average of 54.2

The net income has dropped by 82% year-on-year and by 72% since the previous quarter

Shares outstanding

2.26B

Market cap

$133.82B

Enterprise value

$164.7B

EBIT

$2.67B

EBITDA

$6.72B

Price to earnings (P/E)

92.41

Price to book (P/B)

2.67

Price to sales (P/S)

4.31

EV/EBIT

61.76

EV/EBITDA

24.51

Net debt/EBITDA

4.6

EV/Sales

5.31

EBITDA margin

21.7%

Gross margin

68.1%

Net margin

3.1%

Operating margin

8.7%

Return on assets

1%

Return on equity

2.8%

Return on invested capital

5.8%

Return on capital employed

2.4%

Return on sales

8.6%

Debt to equity

0.94

Free cash flow

$9.75B

Free cash flow per share

$4.32

Book value per share

$22.11

Revenue per share

$13.73

TBVPS

$20.01

Current ratio

1.66

Quick ratio

1.38

Working capital

$12.62B

Dividend yield

2.98%

DPS

$1.76

Payout ratio

275%

BMY's net margin has dropped by 86% year-on-year and by 77% since the previous quarter

The net income has dropped by 82% year-on-year and by 72% since the previous quarter

The operating margin has dropped by 67% year-on-year and by 54% since the previous quarter

The operating income has dropped by 56% year-on-year and by 46% since the previous quarter

Price to earnings (P/E)
Price to book (P/B)
Price to sales (P/S)

Current price to earnings (P/E):

92.41

The stock's price to earnings (P/E) is 154% more than its last 4 quarters average of 36.4 and 71% more than its 5-year quarterly average of 54.2

Bristol Myers Squibb Co's EPS has shrunk by 80% YoY and by 68% QoQ

Current price to book (P/B):

2.67

BMY's P/B is 57% below its 5-year quarterly average of 6.2 and 24% below its last 4 quarters average of 3.5

Bristol Myers Squibb Co's equity has decreased by 3.3% from the previous quarter

Current price to sales (P/S):

4.31

The company's revenue rose by 33% YoY and by 19% QoQ

The price to sales (P/S) is 17% more than the last 4 quarters average of 3.7 but 10% less than the 5-year quarterly average of 4.8

Bristol Myers Squibb Co's ROA has plunged by 93% YoY and by 80% from the previous quarter

The ROE has plunged by 93% YoY and by 80% from the previous quarter

BMY's return on invested capital has dropped by 84% year-on-year and by 58% since the previous quarter

Bristol Myers Squibb Co's return on sales has shrunk by 67% YoY and by 55% QoQ

DPS

$1.76

Dividend yield

2.98%

Payout ratio

275%

Assets vs liabilities

BMY's total assets is 63% greater than its total liabilities

The quick ratio has decreased by 16% YoY but it has increased by 10% QoQ

Bristol Myers Squibb Co's current ratio has decreased by 14% YoY but it has increased by 3.8% from the previous quarter

Debt vs equity

BMY's debt is 6% smaller than its equity

The company's debt to equity has surged by 135% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.